NovoCureBSP:N2VC34 46 FCF Margin % is -10.73% as of Mar. 2026. GuruFocus rates BSP:N2VC34 with a GF Score™ of 46/100 and a GF Value™ of R$8.98 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 815 Medical Devices & Instruments companies, NovoCure ranks worse than 62.45% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. NovoCure's Free Cash Flow for the
three
months ended in Mar. 2026 was R$-98 Mil. NovoCure's Revenue for the
three
months ended in Mar. 2026 was R$910 Mil. Therefore, NovoCure's FCF Margin % for the quarter that ended in Mar. 2026 was -10.73%.
The historical rank and industry rank for NovoCure's FCF Margin % or its related term are showing as below:
BSP:N2VC34'
s FCF Margin % Range Over the Past 10 Years
Min: -151.11 Med: -7.45 Max: 17.03
Current: -7.18
During the past 13 years, the highest FCF Margin % of NovoCure was 17.03%. The lowest was -151.11%. And the median was -7.45%.
BSP:N2VC34's FCF Margin % is ranked worse than 62.45% of 815
companies
in the Medical Devices & Instruments industry
Industry Median: -0.1
vs BSP:N2VC34: -7.18
NovoCure FCF Margin % Related Terms
NovoCure FCF Margin % Historical Data
* Premium members only.
The historical data trend for NovoCure's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSP:N2VC34 vs NEOG, ESTA, AXGN: FCF Margin % Comparison
For the Medical Devices subindustry, NovoCure's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NovoCure FCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, NovoCure's FCF Margin % distribution charts can be found below:
* The bar in red indicates where NovoCure's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NovoCure (BSP:N2VC34) has a FCF Margin % of -10.73% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on NovoCure and its competitors. According to the industry distribution chart, NovoCure ranks #509 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 62.5%.
Is NovoCure's FCF Margin % too high?
NovoCure's current FCF Margin % is -10.73%. Based on the distribution chart, NovoCure ranks #509 out of 815 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, NovoCure has a GF Score™ of 46/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does NovoCure's FCF Margin % compare to NEOG and ESTA?
According to the Medical Devices & Instruments industry distribution chart, NovoCure ranks #509 out of 815 companies for FCF Margin %. This places NovoCure in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Devices & Instruments company?
A good FCF Margin % depends on the Medical Devices & Instruments industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on NovoCure and its competitors. NovoCure's current FCF Margin % is -10.73%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NovoCure stock overvalued right now?
Based on GuruFocus' analysis, NovoCure (BSP:N2VC34) is currently considered Modestly Undervalued. The stock's GF Value™ is R$8.98, compared to a current price of R$7.08 — trading 21.2% below its estimated fair value. The current FCF Margin % is -10.73%. NovoCure's overall GF Score™ is 46/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For NovoCure (BSP:N2VC34), the current FCF Margin % is -10.73% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NovoCure (BSP:N2VC34) Overvalued in 2026?
Based on GuruFocus' analysis, NovoCure stock appears to be undervalued.
The current stock price of R$7.08 is trading 21.2% below its estimated GF Value™ of R$8.98.
GuruFocus considers NovoCure to be Modestly Undervalued.
Key valuation signals for BSP:N2VC34:
FCF Margin %: -10.73%
GF Value™: R$8.98 vs. price of R$7.08 (21.2% below fair value)
No single metric tells the full story. See the BSP:N2VC34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.
46GF Score
Get the complete analysis for BSP:N2VC34
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:N2VC34 has been successfully added to your 
